Telix Pharmaceuticals Valuation
| TLX Stock | 15.76 0.16 1.03% |
At this time, the company appears to be undervalued. Telix Pharmaceuticals has a current Real Value of USD19.02 per share. The regular price of the company is USD15.76. Our model measures the value of Telix Pharmaceuticals from inspecting the company fundamentals such as Price To Book of 20.50 X, operating margin of 0.09 %, and Return On Equity of 0.2 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Telix Pharmaceuticals' valuation include:
Price Book 20.4966 | Enterprise Value 5.2 B | Enterprise Value Ebitda 111.2038 | Price Sales 8.1701 | Forward PE 76.9231 |
Undervalued
Today
Please note that Telix Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Telix Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telix Stock. However, Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.76 | Real 19.02 | Target 32.5 | Hype 15.75 | Naive 13.97 |
The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telix Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telix Pharmaceuticals Limited helps investors to forecast how Telix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Telix Pharmaceuticals' intrinsic value based on its ongoing forecasts of Telix Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Telix Pharmaceuticals' closest peers.
Telix Pharmaceuticals Cash |
|
Telix Valuation Drivers Correlation
Many accounts on the financial statements of Telix Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting Telix's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Telix
Click cells to compare fundamentals
Telix Valuation Trend
Analysing the historical paterns of Telix Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Telix Pharmaceuticals Limited over time and is usually enough for investors to make rational market timing decisions.
Telix Revenue by Product
Telix Pharmaceuticals Total Value Analysis
Telix Pharmaceuticals Limited is at this time expected to have company total value of 5.17 B with market capitalization of 5.28 B, debt of 17.45 M, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Telix Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.17 B | 5.28 B | 17.45 M |
Telix Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Telix Pharmaceuticals has an asset utilization ratio of 124.69 percent. This suggests that the Company is making USD1.25 for each dollar of assets. An increasing asset utilization means that Telix Pharmaceuticals Limited is more efficient with each dollar of assets it utilizes for everyday operations.Telix Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 496.66 M. Total Income to common stockholders was 5.21 M with profit before taxes, overhead, and interest of 0.About Telix Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Telix Pharmaceuticals. We calculate exposure to Telix Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telix Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 308.5 M | 323.9 M | |
| Pretax Profit Margin | 0.01 | 0.01 | |
| Operating Profit Margin | 0.03 | 0.04 | |
| Net Profit Margin | 0.01 | 0.01 | |
| Gross Profit Margin | 0.62 | 0.65 |
Telix Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 323.7 M | |
| Forward Price Earnings | 76.9231 |
Telix Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Telix Pharmaceuticals Limited and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Telix we look at many different elements of the entity such as Telix's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Telix Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Telix Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Telix Pharmaceuticals' worth.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.